R Graham Smith

Title: R Graham Smith: Innovator in Hematological Monitoring

Introduction

R Graham Smith is a notable inventor based in Dallas, TX (US), recognized for his contributions to the field of hematological monitoring. With a total of four patents to his name, he has made significant advancements in the detection and quantitation of hematopoietic tumor cells.

Latest Patents

Smith's latest patents include innovative methods and compositions for monitoring the presence of minimal residual hematopoietic tumor cells, particularly in patients with T-cell acute lymphoblastic leukemia. His inventions utilize nucleic acid hybridization probes to detect alterations in the tal-1 locus on chromosome 1, confirming the presence of residual tumor cells. Additionally, he has developed kits for detecting and quantitating hematopoietic tumor cells in patients, which are crucial for effective monitoring during remission. Another significant patent involves murine monoclonal antibodies that specifically bind to unique antigenic determinants on mammalian terminal deoxynucleotidyl transferases (TdT). These antibodies can detect small numbers of TdT-positive cells, aiding in the monitoring of TdT-positive leukemias and lymphomas across multiple species.

Career Highlights

Throughout his career, R Graham Smith has worked with esteemed organizations such as the University of Texas System and Coulter Corporation. His work has been instrumental in advancing the understanding and treatment of hematological conditions.

Collaborations

Smith has collaborated with notable colleagues, including Kenneth H Kortright and Scott M Malinconico, contributing to the development of innovative solutions in his field.

Conclusion

R Graham Smith's contributions to the field of hematological monitoring through his patents and collaborations highlight his role as a significant innovator. His work continues to impact the detection and treatment of hematological tumors, showcasing the importance of innovation in medical science.